Martingale Asset Management L P Has $24.92 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Martingale Asset Management L P trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 16.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,351 shares of the medical research company’s stock after selling 15,377 shares during the period. Martingale Asset Management L P’s holdings in Amgen were worth $24,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new position in Amgen in the third quarter valued at about $25,000. Hershey Financial Advisers LLC purchased a new position in Amgen in the second quarter valued at about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen during the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter worth about $33,000. Finally, Matrix Trust Co bought a new stake in shares of Amgen during the 3rd quarter worth about $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on AMGN. Barclays upped their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Bank of America upped their price target on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Citigroup lowered their target price on Amgen from $335.00 to $310.00 in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Amgen from $305.00 to $285.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $323.05.

Amgen Stock Up 0.0 %

NASDAQ:AMGN opened at $280.07 on Friday. Amgen Inc. has a 1 year low of $257.80 and a 1 year high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market cap of $150.55 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 2.62 and a beta of 0.60. The stock has a 50-day moving average price of $312.46 and a two-hundred day moving average price of $317.31.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company posted $4.96 earnings per share. As a group, equities analysts expect that Amgen Inc. will post 19.52 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.21%. Amgen’s dividend payout ratio (DPR) is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.